Literature DB >> 21068226

Potential for pregabalin abuse or diversion after past drug-seeking behavior.

Frank A Filipetto1, Christopher P Zipp, Joshua S Coren.   

Abstract

Pregabalin, primarily used to manage neuropathic pain and fibromyalgia, is categorized as a Schedule V drug (ie, lowest potential for abuse) in the US Drug Enforcement Administration's Controlled Substances Act. Because pregabalin is not recognized as a drug with high-abuse potential, data on pregabalin abuse and addiction are lacking. The authors report a case of a 35-year-old woman with a history of opioid-seeking behavior who was prescribed pregabalin for pain control. The patient requested an increase in her medication 2 months after beginning treatment and, after her physician denied her request, subsequently obtained pregabalin from other sources. Over a 28-day period, the patient received a total of 88,500 mg of pregabalin. After learning of the other prescriptions, the patient's physician became suspicious of pregabalin abuse or diversion. In accordance with state medical board guidelines, the patient was discharged from the practice and referred to a local detoxification center.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068226

Source DB:  PubMed          Journal:  J Am Osteopath Assoc        ISSN: 0098-6151


  19 in total

Review 1.  Abuse Potential of Pregabalin: A Systematic Review.

Authors:  Ole Schjerning; Mary Rosenzweig; Anton Pottegård; Per Damkier; Jimmi Nielsen
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

Review 2.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

Review 3.  Misuse and abuse of pregabalin and gabapentin: cause for concern?

Authors:  Fabrizio Schifano
Journal:  CNS Drugs       Date:  2014-06       Impact factor: 5.749

4.  Pregabalin abuse and dependence in Germany: results from a database query.

Authors:  Maximilian Gahr; Roland W Freudenmann; Christoph Hiemke; Makus A Kölle; Carlos Schönfeldt-Lecuona
Journal:  Eur J Clin Pharmacol       Date:  2013-01-05       Impact factor: 2.953

Review 5.  Pregabalin: a review of its use in adults with generalized anxiety disorder.

Authors:  James E Frampton
Journal:  CNS Drugs       Date:  2014-09       Impact factor: 5.749

6.  Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.

Authors:  Jean-Baptiste Bossard; Camille Ponté; Julie Dupouy; Maryse Lapeyre-Mestre; Emilie Jouanjus
Journal:  Clin Drug Investig       Date:  2016-09       Impact factor: 2.859

7.  Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers.

Authors:  James P Zacny; Judith A Paice; Dennis W Coalson
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

8.  Pregabalin abuse among opiate addicted patients.

Authors:  Martin Grosshans; Tagrid Lemenager; Christian Vollmert; Nina Kaemmerer; Rupert Schreiner; Jochen Mutschler; Xenija Wagner; Falk Kiefer; Derik Hermann
Journal:  Eur J Clin Pharmacol       Date:  2013-08-30       Impact factor: 2.953

9.  Pregabalin for the treatment of generalized anxiety disorder: an update.

Authors:  David S Baldwin; Khalil Ajel; Vasilios G Masdrakis; Magda Nowak; Rizwan Rafiq
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

Review 10.  Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies.

Authors:  Amy Wachholtz; Gerardo Gonzalez; Edward Boyer; Zafar N Naqvi; Christopher Rosenbaum; Douglas Ziedonis
Journal:  Subst Abuse Rehabil       Date:  2011-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.